anti-melanoma mab fragments
Various (V09)Various (V09) compound in Bristol Myers Squibb's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
pharma · Melanoma · HIV Infections
Bristol Myers Squibb
Bristol-Myers Squibb
Bristol Myers Squibb drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
3401 Princeton Pike, Lawrence Township, NJ 08648, US HQ
38,146 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 3401 Princeton Pike, Lawrence Township, NJ 08648, US
- Employees
- 38,146
- Programs
- 40
- Drugs
- 17
- Patents
- 25
Bristol Myers Squibb pipeline
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Bristol Myers Squibb drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
daclatasvir
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Bristol Myers Squibb's portfolio.
-
dasatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- SRC inhibitor
-
deucravacitinib
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Non-receptor tyrosine-protein kinase TYK2.
- Target
- Non-receptor tyrosine-protein kinase TYK2
- Mechanism
- Tyrosine-protein kinase TYK2 negative allosteric modulator
-
efavirenz
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
Development asset linked to Bristol Myers Squibb in public FDA and regional records.
-
entecavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.
- Target
- DNA polymerase/reverse transcriptase
- Mechanism
- DNA polymerase/reverse transcriptase inhibitor
-
Development asset linked to Bristol Myers Squibb in public FDA and regional records.
-
ipilimumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
lamivudine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Bristol Myers Squibb's portfolio. Mechanism: Immunostimulant.
- Mechanism
- Immunostimulant
-
relatlimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Bristol Myers Squibb's portfolio. Molecular target: Lymphocyte activation gene 3 protein.
- Target
- Lymphocyte activation gene 3 protein
- Mechanism
- Lymphocyte activation gene 3 protein inhibitor
-
repotrectinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: CD74-ROS1.
- Target
- CD74-ROS1
- Mechanism
- CD74-ROS1 inhibitor
-
stavudine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
vinflunine
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Bristol Myers Squibb's portfolio. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Bristol Myers Squibb in public FDA and regional records. Mechanism: Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor.
- Mechanism
- Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor